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INTRODUCTION
Since the eradication of smallpox, vaccinia virus (VACV) has been 
utilized as a vector for development of vaccines for the preven-
tion of infectious diseases as well as in cancer immunotherapies,1–7 
and oncolytic therapies.8,9 The renewed interest in VACV has driven 
a number of vaccine and therapeutic candidates to clinical trials, 
showing encouraging results for cancer treatment.10,11 To exploit 
VACV to best effect, it needs to be modified by deletion of gene(s) or 
arming with a therapeutic gene.8,12 The thymidine kinase (TK) is the 
gene commonly targeted, but other genes can also be replaced. The 
traditional method for modification of VACV is based on homolo-
gous recombination (HR). However, the frequency of recombination 
is typically less than 0.1%,13 and the purification of recombinant virus 
is tedious and time-consuming. To purify the recombinant virus, a 
number of selection methods have been described including selec-
tion for TK-positive or -negative phenotypes,14 and resistance to 
neomycin15 or mycophenolic acid.16 In addition, β-galactosidase,17 
β-glucuronidase,18 and fluorescent reporter constructs19 have also 
been used. However, the marker gene in the resultant mutant virus 
is not desirable in clinical use, and the Cre/loxP system has been 
used to remove the marker gene from the recombinant virus,20 
however the efficiency of recovery of the recombinant marker-free 
vector was still very low.
The CRISPR (clustered regularly interspaced short palindromic 
repeat)-Cas system is a natural microbial immune mechanism 
against invading viruses and other genetic elements.21–23 There 
are three CRISPR-Cas systems in a range of microbial species.24 
The type II CRISPR-Cas system consisting of the RNA-guided Cas9 
endonuclease (from Streptococcus pyogenes), a single guide RNA 
(sgRNA) and the trans-activating crRNA (tracrRNA), has been devel-
oped for genome editing in eukaryotic cells.25,26 The Cas9 system 
can be designed to cleave any sequence preceding a 5’-NGG-3’ 
PAM sequence in mammalian cells.25,26 It has been a huge success in 
efficient generation of genetically modified cells and animal mod-
els.25–34 It has also been used to modify adenovirus and type I herpes 
simplex virus.35 Recently, we developed an efficient method to edit 
the VACV genome using the CRISPR Cas9 system.36
Here we developed a marker-free system for efficiently and rap-
idly making VACV vectors by combining the CRISPR Cas9 and two 
repair donor vectors targeting the TK and N1L genes respectively. 
The RFP marker gene in the resultant TK-deleted VACA vector can 
be excised using Cre recombinase, and the RFP marker gene in the 
resultant N1L-deleted VACA vector can be excised using Flp recom-
binase. The marker-free system platform developed in this study has 
significant potential for development of new marker-free VACV vec-
tors for clinical application.
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The current method for creation of vaccinia virus (VACV) vectors involves using a selection and purification marker, however inclu-
sion of a gene without therapeutic value in the resulting vector is not desirable for clinical use. The Cre-LoxP system has been used 
to make marker-free Poxviruses, but the efficiency was very low. To obtain a marker-free VACV vector, we developed marker gene 
excision systems to modify the thymidine kinase (TK) region and N1L regions using Cre-Loxp and Flp-FRET systems respectively. 
CRISPR-Cas9 system significantly resulted in a high efficiency (~90%) in generation of marker gene-positive TK-mutant VACV vec-
tor. The marker gene (RFP) could be excised from the recombinant virus using Cre recombinase. To make a marker-free VV vector 
with double gene deletions targeting the TK and N1L gene, we constructed a donor repair vector targeting the N1L gene, which 
can carry a therapeutic gene and the marker (RFP) that could be excised from the recombinant virus using Flp recombinase. The 
marker-free system developed here can be used to efficiently construct VACV vectors armed with any therapeutic genes in the TK 
region or N1L region without marker genes. Our marker-free system platform has significant potential for development of new 
marker-free VACV vectors for clinical application.
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ReSUlTS
Construction of a homologous recombination repair donor vector 
with an excisable RFP gene targeting the VACV TK region
The TK gene in VACV is commonly deleted to engineer a safer vector 
and to insert therapeutic or reporter genes. Therefore, we first con-
structed a repair donor vector to target the TK region for homologous 
recombination. The cassette for HR is cloned between the EcoRI sites 
of the pGEMT-easy vector (Figure 1a). RFP or GFP have frequently 
been used as plaque purification markers to purify engineered 
mutant VACV. However, these genes are not desirable features for 
the virus to possess when moving towards clinical trials as they may 
impair the efficacy of the vector and compromise the safety of the 
treatment. In order to remove RFP in the mutant VACV vector subse-
quently, we adopted the Cre-Loxp system to make RFP excisable after 
a pure TK-deleted VACV vector was obtained. The RFP gene is flanked 
by LoxP sites in the repair donor vector (Figure 1a).
To make the TK repair donor vector more versatile for inserting 
therapeutic genes, we included a multiple cloning site (MCS, with 
PacI, SmaI, PmeI, NheI and MIUI as unique sites) downstream of the 
VV H5 promoter, (Figure 1a). The resulting TK region repair donor 
vector is designated as pTK Loxp-RFP.
Efficient editing of the VACV TK region by gRNA-guided Cas9
Previously, we have shown that homologous recombination of 
VACV can be efficiently mediated by gRNA-guided Cas9 in the N1L 
and A46R regions.36 To gain highly efficient HR in making TK-mutant 
VACV using the TK region repair donor vector pTK Loxp-RFP, we 
designed gRNAs targeting the TK gene and constructed three gRNA 
vectors targeting this region (Figure 1b) (designated as TKgRNA1, 
TKgRNA2, and TKgRNA3 hereafter). We observed successful HR 
events using all three gRNA-guided Cas9, with rates for TKgRNA1, 
TKgRNA2, and TKgRNA3 being 93, 94, and 67%, respectively 
(Supplementary Figure S1 and Supplementary Table S1). The time 
to complete the whole process of obtaining pure mutant VACV is 
approximately 10–12 days. The resulting mutant VACV was desig-
nated vTK-Loxp-RFP (Supplementary Table S2).
RFP is excisable in VTK-Loxp-RFP using Cre recombinase
To remove the RFP selection marker from the resulting TK-deleted 
VACV vector, we employed the Cre-LoxP system (Figure 1a; 
Figure  2a). RFP was removed in about 10% of plaques after vTK-
Loxp-RFP infection of CV-1 cells expressing Cre recombinase (Figure 
2b). The RFP-negative plaques were purified until the RFP-positive 
plaques were completely diluted out upon a few rounds of infec-
tion of CV-1 cells by RFP-negative purification. The deletion of RFP 
in the final mutant VACV vector was also confirmed by polymerase 
chain reaction (PCR) (Figure 2c). The resulting mutant VACV was des-
ignated vTK-RFPnull (Supplementary Table S2).
Generation of TK-deleted VACV vector armed with the therapeutic 
transgene human IL12 without RFP
To test the potential of the TK region repair donor pTK Loxp-RFP 
for introducing therapeutic genes into the TK-mutant VACV, we 
cloned human Interleukin-12 (hIL-12) into the MCS of the vector, 
Figure 1 gRNA-guided Cas9 induces homologous recombination in the TK region of VACV. (a) Schematic of the shuttle vector pTK Loxp-RFP (TK gene 
repair donor vector) cassette and repaired target region on the VACV genome. H5 is the promoter driving gene expression. RFP refers to red fluorescent 
protein. (b) The sequence of TK gRNA1, 2 and 3 and their alignment on the TK gene. PAM is underlined. TK, thymidine kinase; VACV, vaccinia virus.
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the expression of hIL-12 was driven by the H5 promoter (Figure 3a) 
(designated as pTK Loxp-RFP-hIL12). TK gRNA1 and Cas9 plasmids 
were cotransfected into CV-1 cells to facilitate HR using pTK Loxp-
RFP-hIL12. The rate of successful HR in RFP-positive plaques was 
80% (8/10) (Figure 3b), and the resulting mutant VACV was desig-
nated vTK-hIL2-RFP (Supplementary Table S2). hIL-12 was expressed 
efficiently in the mutant VACV (Figure 3c). To remove RFP from the 
mutant VACV, pCAG-Cre was transfected into the CV-1 cells 24 
hours before infection with the mutant VACV (Figure 4a). RFP was 
successfully removed from numerous plaques (Figure 4b). One 
RFP-negative plaque was purified further by infection of CV-1 cells 
until no RFP-positive plaques were present. The deletion of RFP in 
the mutant VACV VTK-hIL12 was confirmed by amplification of RFP 
using PCR (Figure 4c), and hIL12 expression was maintained after 
RFP excision (Figure 4d). The resulting mutant VACV was designated 
vTK- hIL2-RFPnull (Supplementary Table S2).
Construction of a homologous recombination repair donor vector 
for the VACV N1L region with excisable RFP
To make VACV a more potent oncolytic virus, we further engineered 
a TK-deleted VACV by deletion of the virulence factor N1L gene, and 
the double gene-deleted VACV vector shows better selectivity and 
antitumour potency compared to the VACV with only TK deletion 
(unpublished data). Since we had exploited the Cre-Loxp system in 
removing the RFP gene from the TK-deleted virus, we in turn used 
the Flp-FRT system incorporated into the N1L region in the repair 
donor vector to excise the RFP from the mutant N1L VACA, in which 
the cassette for HR is cloned between the HindIII and KpnI sites of 
the pUC19 vector with the RFP gene flanked by FRT sites in the 
repair donor vector (Figure 5a).
To make the N1L repair donor vector more versatile for carrying 
therapeutic genes, we included a MCS downstream of the H5 pro-
moter. SnaBI, SalI, EcoRV, PmeI, BglII, NheI, and PacI are unique sites 
in the MCS, which can be used for cloning of any therapeutic genes. 
The H5 promoter was used to drive RFP and potential transgene 
expression in the MCS of the vector (Figure 5a). The resulting N1L 
region repair donor vector is designated as pN1L FRT-RFP.
RFP is excisable from mutant VACV using Flp recombinase
We previously showed that HR in the N1L region was efficiently 
achieved using the gRNA vector N1L gRNA2-guided Cas9.36 N1L 
gRNA2 and Cas9 were cotransfected into CV-1 cells to facilitate 
HR using pN1L FRT-RFP (the backbone virus used for HR was vTK-
RFPnull). The rate of successful HR in RFP-positive plaques was about 
78% (11/14) (Figure 5b), and the resulting mutant VACV was desig-
nated vTK-N1L-RFP (Supplementary Table S2). To remove the RFP 
selection marker from the resulting Flp-deleted VACV, we employed 
the Flp-FRT system (Figure 5a, Figure 6a). RFP was removed in about 
10% of plaques after vN1L-FRT-RFP infection of CV-1 cells express-
ing Flp recombinase (Figure 6b). The RFP-negative plaques were 
purified until the RFP-positive plaques were completely diluted 
out upon a few rounds of infection of CV-1 cells by RFP-negative 
selection. The deletion of RFP in the final mutant VACV was also 
confirmed by PCR (Figure 6c). The resulting mutant VACV was desig-
nated vTK-N1L-RFPnull (Supplementary Table S2).
Generation of N1L-mutant VACV armed with the therapeutic 
transgene human IL-21 without RFP
To test the potential of the N1L region repair donor pN1L Flp-RFP 
for introducing therapeutic genes into the N1L-mutant VACV, we 
cloned human IL-21 (hIL-21) into the MCS of the vector under 
the H5 promoter (Figure 7a) (designated as pN1L FRT-RFP-hIL21). 
N1L gRNA2 and Cas9 were cotransfected into CV-1 cells to facili-
tate HR using pN1L Flp-RFP-hIL21, and the backbone virus used 
for HR was vTK-RFPnull. The rate of successful HR in RFP-positive 
plaques was 88.9% (8/9) (Figure 7b), and the resulting mutant 
VACV was designated vTK-N1L-hIL21-RFP (Supplementary Table 
S2). hIL-21 was expressed efficiently in the mutant VACV (Figure 
7c). To remove RFP from the mutant VACV, pCAG-Flp was trans-
fected into the CV-1 cells 24 hours before infection using the 
mutant VACV (Figure 8a). RFP was successfully removed from 
numerous plaques (Figure  8b). One RFP-negative plaque was 
purified further until no RFP-positive plaques were present. 
The deletion of RFP in the mutant VACV VN1L-hIL-21 was con-
firmed by amplification of RFP using PCR (Figure 8c), and hIL-21 
expression was maintained after RFP removal (Figure 8d). The 
resulting mutant VACV was designated vTK-N1L-hIL21-RFPnull 
(Supplementary Table S2). In addition, using the pN1L FRT-RFP 
vector system, we successfully made the vTK-N1L-mIL21-RFPnull 
virus (Supplementary Result, Supplementary Figures S2 and S3, 
Supplementary Table S2).
DISCUSSION
The efficiency of the traditional HR method for constructing mutant 
VACV is less than 0.1%.13 Recently we showed that the efficiency 
of mutant VACV construction can be improved significantly using 
gRNA-guided Cas9 system, by which we generated mutant VACV 
Figure 2 The RFP selection marker in modified VACV is excisable by Cre 
recombinase. (a) Schematics of Cre targeting Loxp sites spanning RFP in 
VACV before and after RFP is removed by Cre. (b) Images of plaques of 
TK-LoxP-RFP “in” (lower panel) or “not in” (upper panel) presence of Cre 
expression. Pure plaques of TK-LoxP-RFP were used to infect CV-1 cells with 
or without Cre expression. The RFP-negative plaque (indicated with p) was 
picked up and purified further. (c) RFP gene deletion was verified by PCR in 
pure mutant VACV obtained from vTK LoxP-RFP virus after RFP was excised 
by Cre in CV-1 cells. A46R gene amplification was used as a DNA control. 
Ctr is the control sample from the TK-LoxP-RFP virus, Cre is the sample from 
a pure plaque after RFP was removed by Cre from the TK-LoxP-RFP virus. 
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Figure 3 gRNA-guided Cas9 induces homologous recombination in the TK region with a repair donor vector expressing hIL12. (a) Schematic of the 
homologous recombination cassette of the shuttle vector (TK gene repair donor vector) pTK LoxP-RFP-hIL12 expressing hIL12 and repaired target region 
on the VACV genome. (b) TK gene deletion was verified by polymerase chain reaction (PCR) in pure plaques of mutant VACV obtained from TKgRNA1-
guided Cas9-induced homologous recombination. Partial LacZ gene was amplified by PCR to confirm the HR in TK region, A46R gene amplification was 
used as a DNA control. 8/10 plaques show TK deletion. (c) hIL12 expression was detected by enzyme-linked immunosorbent assay from the supernatant of 


































Figure 4 The RFP selection marker in mutant vTK-Loxp-RFP-hIL12 is excisable by Cre recombinase. (a) Schematic of Cre targeting LoxP sites 
spanning RFP in VACV before and after RFP was removed by Cre. (b) Images of plaques of vTK-Loxp-RFP-hIL12 “in” (lower panel) or “not in” (upper 
panel) the presence of Cre expression in CV-1 cells. A pure plaque of vTK-LoxP-RFP-hIL12 was used to infect CV-1 cells with or without Cre 
expression. The RFP-negative plaque (indicated with p) was picked up and purified further. (c) RFP gene deletion was verified by polymerase chain 
reaction in pure mutant VACV obtained from vTK-LoxP-RFP-hIL12 virus after RFP was excised by Cre in CV1 cells. A46R gene amplification was used 
as a DNA control. Ctr is the control sample from vTK-LoxP-RFP-hIL12 virus; Cre is the sample from pure plaque after RFP was removed by Cre from 
vTK-LoxP-RFP-hIL12 virus. (d) hIL12 expression detected from the supernatant of CV-1 cells infected with pure vTK-hIL12 virus by enzyme-linked 
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with deletion of the N1L or A46R regions.36 We used the gRNA-
guided Cas9 system to achieve high HR efficiency in making mutant 
VACA with repair donor vectors with excisable marker genes.
VACV is usually modified by gene deletion to create a more 
selective virus for infection and lysis of tumour cells. This improves 
the efficacy of the treatment as well as its safety. Deletion of the 
TK region is one of the most common modifications to the VACV 
genome to achieve its selectivity.8,9,12,37 We created the TK region 
repair donor vector pTK Loxp-RFP, which has the features of an 
excisable RFP selection marker flanked by LoxP sites, and unique 
restriction enzyme sites that can accommodate any therapeutic 
gene in the MCS, under control of an endogenous, stable H5 pro-
moter. Combination of this donor vector with TK gRNA-guided Cas9 
system was used to efficiently and rapidly produce TK-deleted VACV 
armed with a therapeutic gene, hIL-12 as an exemplar. Comparing 
three TK gRNAs, TKgRNA1- and TKgRNA2-guided Cas9 can induce 
more than 90% HR, subsequently, one of these two TK gRNA vec-
tors was used for TK region HR. After construction of the TK-deleted 
VACV using the donor vector pTK Loxp-RFP or pTK Loxp-RFP-hIL-12, 
RFP was successfully removed. The removal of RFP using Cre recom-
binase system does not alter the expression of hIL-12 in vTK-hIL-12. 
Within just 10–12 days, a mutant VACA was made using the above 
method.
As the MCS of the TK donor vector pTK Loxp-RFP has the potential 
to accommodate any therapeutic gene, combination of this donor 
vector with TK gRNA1- (or TKgRNA2)-guided Cas9 would efficiently 
engineer a TK-mutant VACA armed with a therapeutic gene free of 
the plaque purification marker RFP.
VACV has distinctive features for development as a tumor-tar-
geted oncolytic virus for cancer treatment,5,38–40 TK-deleted Lister 
strain VACV is an attractive platform for development of the next 
generation of oncolytic viruses.39 The next generation of tumor-tar-
geted oncolytic VACV should be safer and more potent compared 
to TK-deleted VACV. The VV N1L gene (called L025 in the VVL strain) 
Figure 5 gRNA-guided Cas9 induces homologous recombination in the N1L region of VACV. (a) Schematic of the shuttle vector pN1L FRT-RFP (N1L 
gene repair donor vector) cassette and repaired target region on the VACV genome. (b) N1L gene deletion was verified by polymerase chain reaction 
(PCR) in pure plaques of mutant VACV obtained from N1L gRNA2 guided Cas9-induced HR. Partial L026 gene and Partial N1L gene was amplified by 
PCR to confirm the HR in N1L region. A46R gene amplification was used as a DNA control. 11/14 plaques show HR in the N1L region. HR, homologous 
recombination; RFP, red fluorescent protein; VACV, vaccinia virus.
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Figure 6 The RFP selection marker in modified VACV is excisable by 
Flp recombinase. (a) Schematics of Flp targeting FRT sites spanning 
RFP in VACV before and after RFP is removed by Flp. (b) Images of 
plaques of N1L-LoxP-RFP “in” (lower panel) or “not in” (upper panel) 
presence of Flp expression. Pure plaques of N1L-FRT-RFP were used 
to infect CV-1 cells with or without Flp expression. The RFP-negative 
plaque (indicated with p) was picked up and purified further. (c) RFP 
gene deletion was verified by PCR in pure mutant VACV obtained 
from vN1L LoxP-RFP virus after RFP was excised by Flp in CV-1 cells. 
A46R gene amplification was used as a DNA control. Ctr is the control 
sample from the N1L-LoxP-RFP virus; FlP is the sample from a pure 
plaque after RFP was removed by Flp from the N1L-LoxP-RFP virus. 
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Figure 7 gRNA-guided Cas9 induces homologous recombination in the N1L region with a repair donor vector expressing hIL21. (a) Schematic of the 
homologous recombination cassette of the shuttle vector (N1L repair donor vector) pN1L FRT-RFP-hIL21 expressing hIL21 and repaired target region 
on the VACV genome. (b) N1L gene deletion was verified by PCR in pure plaques of mutant VACV obtained from N1L gRNA2-guided Cas9-induced 
homologous recombination. Partial N1L and Partial L026 gene amplification was used to confirm the HR in N1L region, A46R gene amplification was 
used as a DNA control. Eight out of nine plaques show N1L deletion. (c) hIL21 expression was detected by enzyme-linked immunosorbent assay from 
the supernatant of pure vN1L-Flp-RFP-hIL21 virus-infected CV-1 cells. HR, homologous recombination; RFP, red fluorescent protein; TK, thymidine 




FRT FRT Vaccinia DNA





























Figure 8 The RFP selection marker in mutant vN1L-Flp-RFP-hIL21 is excisable by Flp. (a) Schematic of Flp targeting FRT sites spanning RFP in VACV before and 
after RFP was removed by Flp. (b) Images of plaques of vN1L-Loxp-RFP-hIL21 “in” (lower panel) or “not in” (upper panel) the presence of Flp expression in CV-1 
cells. A pure plaque of vN1L-LoxP-RFP-hIL21 was used to infect CV-1 cells with or without Flp expression. The RFP-negative plaque (indicated with p) was picked 
up and purified further. (c) RFP gene deletion was verified by PCR in pure mutant VACV obtained from vN1L-Flp-RFP-hIL21 virus after RFP was excised by Flp 
in CV-1 cells. A46R gene amplification was used as a DNA control. Ctr is the control sample from vN1L-FRT-RFP-hIL21 virus, Flp is the sample from pure plaque 
after RFP was removed by Flp from vN1L-Flp-RFP-hIL21 virus. (d) hIL21 expression detected by enzyme-linked immunosorbent assay from the supernatant of 
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is a major virulence gene that when disrupted,41,42 was shown to 
significantly reduce pulmonary toxicity following various routes 
of administration into animal models. N1L gene disruption led to 
a significant reduction in the neurovirulence of VACV, with reduced 
viral titres in the brains of mice that had been directly inoculated.43 
Recently, we demonstrated that deletion of N1L gene can signifi-
cantly enhance antitumour immunity by oncolytic VACV (unpub-
lished data). Therefore, N1L gene is another potential region that 
can be deleted to insert therapeutic genes. We have shown here 
that the Flp-FRT system is another site-specific recombination sys-
tem to efficiently excise reporter genes.44 The VTK-N1L-RFPnull, VTK-
N1L-hIL21-RFPnull, and VTK-N1L-hIL12-RFPnull viruses could be 
useful in the construction of vectors for the clinic.
MATeRIAlS AND MeTHODS
Cell culture and transfection
CV-1 (Monkey kidney fibroblast) cells were maintained in Dulbecco’s 
Eagle’s medium (Life Technologies, Paisley, UK) supplemented with 5% 
fetal bovine serum (Hyclone, Northumberland, UK), 100 U/m; penicillin, and 
100 μg/ml streptomycin at 37 °C with 5% CO2. CV-1 cells were transfected 
using Effectene (Qiagen, Manchester, UK) according to the manufacturer’s 
instructions.
Restriction enzymes
All restriction enzymes were bought from New England Biolabs (Hitchin, UK).
Plasmids
pCAG-Cre (Addgene,#13775), pCAG-Flpe (Addgene, #13787), and pGEM-
Teasy (Promega, UK) were purchased commercially.
Plasmid purification
Plasmids were purified using the Qiagen miniprep kit (Qiagen, Manchester, 
UK) according to the manufacturer’s instructions.
Cloning of gRNAs
The target RNA sequences for the TK region of VACV were selected follow-
ing the principle stated previously.27 gRNA oligos with extra ends for clon-
ing were synthesized (Sigma, UK) and cloned into the gRNA cloning vector 
PB-gRNA-Bsa1 vector45 as follows:
PB-gRNA-BsaI vector was digested with BsaI to produce sticky ends on 
the backbone as 3-GAAC-5 and 3-GTTT-5. After annealing and ligation, a 
20 bp sequence will replace the 400 bp unrelated sequence in the backbone, 
which was checked by XhoI-BglII digestion (If ligation works, 0.5k + 1.7K + 
3.9K bands will be seen; if not, 0.9K + 1.7K + 3.9K bands will be seen). The 
sequences of the gRNA oligos are shown in the Supplementary Figure S1 
and Table S1. The individual gRNA coding sequences in the resulting vector 
were confirmed by Sanger sequencing. The resulting plasmids were desig-
nated TKgRNA1, TKgRNA2, and TKgRNA3.
Construction of a TK-directed shuttle vector containing RFP flanked 
by LoxP sites for homologous recombination
The left arm for TK region (TK left arm) homologous recombination was 
amplified by PCR from Lister strain of VACV DNA with forward primer 
5′-TCAAACATCTGCGTTATCA-3′ and reverse primer 5′-CTCGAG GGTACCTATTT 
ATGATTATTTCTCGCTTTCAATTTAACACAACCCTCAAGAACCTTTGTATTTATTTTCA 
ATTTTTATA ACTTCGTATAGCATACATTATACGAAGTTATCGTTCATGATGACAA 
TAAAGA-3′ (the elements of this primer are as follows: XhoI and KpnI are 
underlined; H5 promoter; loxP; and reverse primer sequence to amplify VACV 
gene). The right arm for the TK region (TK right arm) homologous recombi-
nation was amplified by PCR from Lister strain of VACV DNA with forward 
primer 5′-AAGCTTGTTTAAACGCTAGCACGCGTGTAGAAAGTG TTACATCGACTC 
A-3′ (HindIII, PacI, NheI and MIuI are underlined) and reverse primer 5′-CTCGA 
GATTTCAGCTGAATATGAAGGA-3′ (XhoI is underlined). RFP was ampli-
fied by PCR using dsRED (Clonetech) as the template with forward primer 
5′-GGTACCGCTACCG GACTCAGATCCA-3′ (KpnI is underlined) and reverse 
primer 5′-AAGCTTCCCGGGTTAAT TAATATTTATGATTATTTCTCGCTTTCAATTTAAC 
ACAACCCTCAAGAACCTTTGTATTTATTTTCAATTTTATAACTTCGTATAGCATAC 
ATTATACGAAGTTATCGCCTTAAGATACATTGATGAG-3′ (HindIII, SmaI and PacI 
are underlined; H5 promoter; loxP; and reverse primer sequence to amplify 
the RFP gene). Extensor Long PCR ReddyMix Master Mix (Thermo Scientific, 
UK) was used for all PCR reactions. The PCR products were resolved on aga-
rose gel and purified from the gel using a gel purification kit (Qiagen). All 
PCR fragments were cloned into the pGEMT easy vector; the sequence of 
individual cloned fragments was verified by Sanger sequencing. The RFP-H5 
fragment was released by KpnI and HindIII digest from the pGEMT-easy RFP-
H5 plasmid. The TK right arm was released by HindIII and XhoI digest from 
the pGEMT-easy TK right arm plasmid. The RFP-H5 and TK right arm were 
cloned into the KpnI and XhoI sites of pGEMT-easy-TK left arm-H5 plasmid. 
The resulting plasmid was the TK gene repair donor vector pGEMT-easy-TK 
left arm-Loxp-H5-RFP-Loxp-H5-TK right arm, which is the shuttle vector for 
the homologous recombination into the TK region, and is referred to as TK 
Loxp RFP vector hereafter. The sequences of individual cloned fragments 
were verified by Sanger sequencing.
Construction of a shuttle vector TK-Loxp-RFP-hIL-12
Human IL-12 (hIL-12) was released by SnaBI and NheI restriction digestion 
from pORF hIL-12 (Invivogen, UK). The released hIL-12 was cloned into the 
PmeI and NheI sites of the TK Loxp RFP vector. The resulting plasmid is TK 
Loxp RFP-hIL-12.
Construction of an N1L-directed shuttle vector containing RFP 
flanked by FRT sites for homologous recombination
The left arm for N1L region (N1L left arm) homologous recombina-
tion was amplified by PCR from Lister strain of VACV DNA with forward 
primer 5′-AAGCTTGTCCTATCGTAGGCGATAGA-3′ (HindIII is underlined) and 
reverse primer 5′-GGTACC GAATTCGAATTCCTCGAGTATTTATGATTATTTCTCG 
CTTTCAATTTAACACAACCCTCAA GAACCTTTGTATTTATTTTCAATTTTTGAAGTT 
CCTATACTTTCTAGAGAATAGGAACTT CGATCTAATGATTGATC TATATGGTG-3′ 
(the elements of this primer are as follows: XhoI and KpnI are underlined; 
H5 promoter; FRT site; and reverse primer sequence to amplify VACV gene). 
The right arm for N1L region (N1L right arm) homologous recombination 
was amplified by PCR from Lister strain of VACV DNA with forward primer 
5′-AAGCTT GTTTAAAC AGATCT GCTAGC TTAATTAA ATCTAATAAGTAGAGTCCT-
CAT GCT-3′ (HindIII PmeI, BglII, NheI and PacI are underlined) and reverse 
primer 5′-GGTACCCGGAAGGTAGTAGCATGGA-3′ (KpnI is underlined). RFP 
was amplified by PCR using dsRED (Clonetech) as the template with forward 
primer 5′-CTCGAG GCTACCG GACTCAGATCCA-3′ (XhoI is underlined) and 
reverse primer 5′-AAGCTT GATATC GTCGACTACGTATATTTATGATTATTTCTCG 
CTTTCAATTTAACACAACCCTCAAGAACC TTTGTATTTATTTTCAATTTTTGAAGT 
TCCTATACTTTCTAGAGAATAGGAACTTCCGCCTTAA GATACATTGATGAG-3′ (the 
elements of this primer are as follows: HindIII, EcoRV, SalI, and SnaBI are 
underlined; H5 promoter; FRT site; and reverse primer sequence to amplify 
the RFP gene). Extensor Long PCR ReddyMix Master Mix was used for all PCR 
reactions. The PCR products were resolved on agarose gel and purified from 
the gel using a gel purification kit. All PCR fragments were cloned into the 
pGEMT easy vector, and the sequence of individual cloned fragments was 
verified by Sanger sequencing. The RFP-H5 fragment was released by XhoI 
and HindIII digestion from the pGEMT-easy RFP-H5 plasmid. The N1L right 
arm was released by HindIII and KpnI digestion from the pGEMT-easy N1L 
right arm plasmid. The RFP-H5 and N1L right arm were cloned into the KpnI 
and XhoI sites of the pGEMT-easy-N1L left arm-H5 plasmid. The resulting 
plasmid was the N1L gene repair donor vector pGEMT-easy-N1L left arm-
FRT-H5-RFP-FRT-H5-N1L right arm, which is the shuttle vector for the homol-
ogous recombination into the N1L region, and is referred to as N1L Loxp RFP 
vector hereafter. The sequences of individual cloned fragments were verified 
by Sanger sequencing.
Construction of shuttle vector N1L-FRT-RFP-hIL21
Human IL-21 (hIL-21) was released by SalI and BglII restriction digest from 
pORF hIL-21 (Invivogen). The released hIL21 was cloned into the SalI and BglII 
sites of the N1L FRT RFP vector. The resulting plasmid is N1L FRT RFP-hIL-21.
Construction of shuttle vector N1L-FRT-RFP-mIL-21
Mouse IL-21 (mIL-21) was released by SalI and BglII restriction digestion 
from pORF mIL-21 (Invivogen). The released mIL-21 was cloned into the SalI 
and BglII sites of the N1L FRT RFP vector. The resulting plasmid is N1L FRT 
RFP-mIL-21.
Virus production and titration
VACV was produced and titrated as described previously using CV-1 cells to 
propagate the virus.5
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Cas9-mediated homologous recombination
2 × 105 CV-1 cells were seeded into each well of a six-well plate the day before 
transfection. gRNA vector was cotransfected with Cas9 into CV-1 cells in the 
six-well plate. The next day, the transfected well was infected with 0.01 pfu/
cell of backbone virus. The repair donor vector for homologous recombina-
tion was transfected into infected wells 2 hours after virus infection. Cells 
were harvested 24 hours later, and frozen at −80 °C for plaque purification 
(Supplementary Figure S4).
Plaque purification of mutant VACV
3 × 105 CV-1 cells were seeded into each well of a six-well plate the day 
before virus infection. 0.5 µl of lysate was used to infect one six-well plate 
of CV-1 cells, six 6-well plates were infected for each recombinant virus (first 
round of virus purification). After 2 days of infection, RFP-positive plaques 
were picked up under fluorescence microscopy using a 20× objective lens 
(Olympus). After one freeze-thaw cycle, the lysate was added into two six-
well plates of 80% confluent CV-1 cells. The following day, one RFP-positive 
plaque was picked from each of the first round plaque-infected six-well 
plates, and put into one cryovial containing 200 µl serum-free Dulbecco’s 
Eagle’s medium. After one freeze-thaw cycle, the lysate was added into two 
six-well plates with CV-1 cells seeded the day before infection (second round 
plaque purification). Plaque purification continued as above for three to five 
more rounds until the plaques were pure.
Verification of mutant TK VACV
CV-1 Cells were infected with purified plaques. Infected cells were 
harvested after 2 days of infection. VACV DNA was extracted using a 
DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s 
protocol. The VVL15 virus (TK-deleted VACV with LacZ inserted into 
TK region) was used as the backbone virus for HR. To verify the dele-
tion of LacZ gene in the TK region, part of LacZ gene was ampli-
fied by PCR using forward primer: 5′-TCGGCTTACGGCGGTGA-3′ and 
reverse primer: 5′-GCAAGTGTATCTGCCGT-3′. A control DNA fragment 
spanning the A46R and A47L genes was amplified by PCR using for-
ward primer: 5′-TTGGCTATTAAACAGTA TGGA-3′ and reverse primer: 
5′-GGATCCCGATAACAAATG-3′. Extensor Long PCR ReddyMix Master Mix was 
used for all PCR reactions. The PCR products were analyzed by 1% agarose 
gel electrophoresis.
Verification of mutant N1L VACV
CV-1 Cells were infected with purified plaques. Infected cells were harvested 
after 2 days of infection. VACV DNA was extracted using DNeasy Blood & 
Tissue Kit according to the manufacturer’s protocol. To verify the deletion of 
the N1L gene, a DNA fragment spanning the N1L gene and the L026 gene 
was amplified by PCR using forward primer: 5′-TATCTAGCAATGGACCGT-3′ 
(within the N1L gene) and reverse primer: 5′-CCGAAGGTAGTAGCATGGA 
(within the L026 gene). A control DNA fragment spanning the A46R and A47L 
genes was amplified by PCR using forward primer: 5′-TTGGCTATTAAACAGTA 
TGGA-3′ and reverse primer: 5′-GGATCCCGATAACAAATG-3′. Extensor Long 
PCR ReddyMix Master Mix was used for all PCR reactions. The PCR products 
were analyzed by 1% agarose gel electrophoresis.
Excision of RFP using Cre recombinase
pCAG-Cre was transfected into CV-1 cells in one well of six-well plate. Twenty-
four hours after transfection with pCAG-Cre, CV-1 cells were infected with 
100–200 pfu of Cre-RFP VACV. Two days later, RFP-negative plaques were 
picked (Supplementary Figure S5), and used to infect CV-1 cells in six-well 
plates to purify RFP-negative plaques. Then RFP-negative plaques were picked 
and CV-1 cells were infected until no RFP-positive plaques were seen under 
fluorescence microscopy every 2 days (Supplementary Figure S6). The excision 
of RFP from the virus by Cre recombinase was tested by PCR of RFP gene.
Excision of RFP using Flp recombinase
pCAG-Flpe was transfected in CV-1 cells in one well of six-well plate. Twenty-
four hours after transfection with pCAG-Flpe, CV-1 cells were infected with 
100–200 pfu of Flp-RFP VACV. Two days later, RFP-negative plaques were 
picked (Supplementary Figure S5), and used to infect CV-1 cells in six-well 
plates to purify RFP-negative plaques. Then RFP-negative plaques were picked 
and CV-1 cells were infected until no RFP-positive plaques were seen under 
fluorescence microscopy every 2 days (Supplementary Figure S6). The excision 
of RFP from the virus by Flp recombinase was tested by PCR of RFP gene.
Verification of RFP-deleted mutant VACV
After purification of RFP-negative plaques upon the excision of RFP by 
Cre or Flp recombinase (RFP was amplified by PCR using forward primer 
5′-GCTACCGGACTCAGATCCA-3′ and reverse primer 5′-CGCCTTAAGATACATTG 
ATGAG-3′ to verify the deletion of RFP in the RFP-negative mutant VACV, A 
control DNA fragment spanning the A46R and A47L genes was amplified 
by PCR using forward primer: 5′-TTGGCTATTAAACAGTATGGA-3′ and reverse 
primer: 5′-GGATCCCGATAACAA ATG-3′.
Enzyme-linked immunosorbent assay
The expression of hIL-12 was detected by enzyme-linked immunosorbent 
assay (eBioscience, UK) following the manufacturer’s instructions. The 
expression level of hIL1-2 was recorded as OD value. The expression of hIL-
21 was detected by enzyme-linked immunosorbent assay (eBioscience) fol-
lowing the manufacturer’s instructions. The expression level of hIL-21 was 
recorded as OD value.
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